Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK inhibitor dose tapering in low disease activity rheumatoid arthritis
2023-509788-25-00Phase 4Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of baricitinib, upadacitinib, tofacitinib and filgotinib in rheumatoid arthritis (RA) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Proportion of patients on JAK inhibitor in CDAI low disease activity at 12 months. Planned start Jun 2024; status: authorised.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2023-509788-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509788-25-00.